Emily A Pinheiro1, Catherine S Stika2. 1. Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 3-2303, Chicago, IL 60611, USA. Electronic address: c-stika@northwestern.edu.
Abstract
Pharmacologic interventions play a major role in obstetrical care throughout pregnancy, labor and delivery and the postpartum. Traditionally, obstetrical providers have utilized standard dosing regimens developed for non-obstetrical indications based on pharmacokinetic knowledge from studies in men or non-pregnant women. With the recognition of pregnancy as a special pharmacokinetic population in the late 1990s, investigators have begun to study drug disposition in this unique patient dyad. Many of the basic physiologic changes that occur during pregnancy have significant impact on drug absorption, distribution and clearance. Activity of Phase I and Phase II drug metabolizing enzymes are differentially altered by pregnancy, resulting in drug concentrations sufficiently different for some medications that efficacy or toxicity is affected. Placental transporters play a major dynamic role in determining fetal drug exposure. In the past two decades, we have begun to expand our understanding of obstetrical pharmacology; however, to truly optimize pharmacologic care of our pregnant patients and their developing fetus, additional research is critically needed.
Pharmacologic interventions play a major role in obstetrical care throughout pregnancy, n class="Disease">labor and delivery and the postpartum. Traditionally, obstetrical providers have utilized standard dosing regimens developed for non-obstetrical indications based on pharmacokinetic knowledge from studies in men or non-pregnant women. With the recognition of pregnancy as a special pharmacokinetic population in the late 1990s, investigators have begun to study drug disposition in this unique patient dyad. Many of the basic physiologic changes that occur during pregnancy have significant impact on drug absorption, distribution and clearance. Activity of Phase I and Phase II drug metabolizing enzymes are differentially altered by pregnancy, resulting in drug concentrations sufficiently different for some medications that efficacy or toxicity is affected. Placental transporters play a major dynamic role in determining fetal drug exposure. In the past two decades, we have begun to expand our understanding of obstetrical pharmacology; however, to truly optimize pharmacologic care of our pregnant patients and their developing fetus, additional research is critically needed.
Authors: Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz Journal: Am J Obstet Gynecol Date: 2011-04-22 Impact factor: 8.661
Authors: David M Haas; Sara K Quinney; Jayanti M Clay; Jamie L Renbarger; Mary F Hebert; Shannon Clark; Jason G Umans; Steve N Caritis Journal: Am J Perinatol Date: 2012-08-08 Impact factor: 1.862
Authors: Sara Eyal; Thomas R Easterling; Darcy Carr; Jason G Umans; Menachem Miodovnik; Gary D V Hankins; Shannon M Clark; Linda Risler; Joanne Wang; Edward J Kelly; Danny D Shen; Mary F Hebert Journal: Drug Metab Dispos Date: 2010-01-29 Impact factor: 3.922
Authors: Christina Fotopoulou; Rebekka Kretz; Steffen Bauer; J C Schefold; Bettina Schmitz; Joachim W Dudenhausen; Wolfgang Henrich Journal: Epilepsy Res Date: 2009-03-09 Impact factor: 3.045
Authors: Vera E Bukkems; Coca Necsoi; Carmen Hidalgo Tenorio; Coral Garcia; Irene Alba Alejandre; Fabian Weiss; John S Lambert; Astrid van Hulzen; Olivier Richel; Lindsey H M Te Brake; Eric van der Meulen; David Burger; Deborah Konopnicki; Angela Colbers Journal: Clin Infect Dis Date: 2022-09-10 Impact factor: 20.999